Background: Impaired insulin sensitivity (IS) predicts complications and mortality in type 1
| INTRODUCTION
Impaired insulin sensitivity (IS) is common not only in type 2 diabetes but also type 1 diabetes (T1D). 1 Tissue uptake of blood glucose is lower than normal, resulting in hyperglycaemia despite higher endogenous or exogenous insulin levels, which may lead to complications such as retinopathy, nephropathy, and cardiovascular disease. 2, 3 Insulin sensitivity can be quantified by using the gold-standard hyperinsulinaemiceuglycaemic (HIEG) clamp, 4 but the procedure is labour-and time-intensive. Insulin resistance or IS can also be estimated by using validated mathematical models such as the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) 5 and the Simple Index of Insulin Sensitivity from the oral glucose tolerance test (SI is OGTT) 6 , both highly correlated with HIEG clamp results in nondiabetic individuals [5] [6] [7] . However, as neither HOMA-IR nor SI is OGTT is a valid measure in T1D due to the lack of endogenous insulin, an alternative model of IS called the estimated glucose disposal rate (eGDR) was previously derived specifically for patients with T1D. 8 Impaired IS calculated by using eGDR has been shown to be clinically significant in T1D as it is strongly associated with longer T1D duration 9 and predicts diabetes complications and mortality. 10, 11 To attenuate the burden of hyperglycaemia and complications in T1D, islet cell transplantation is a minimally invasive therapy currently being tested in clinical trials as a potential durable treatment for T1D. 12, 13 Briefly, islets are isolated from a deceased human donor pancreas, then transplanted into a T1D patient's liver via the portal vein. 13 The goal is to provide a sufficient number of islets to restore adequate endogenous insulin to control blood glucose and eliminate severe hypoglycaemic episodes. However, not all recipients maintain long-term insulin independence, and some experience graft failure. 14 Therefore, optimizing recipients' IS could potentially lead to more durable islet graft function by placing less metabolic demand on the transplanted beta-cells. Indeed, research has shown that islet transplant improves IS as measured by the HIEG clamp within 6 to 7 months following transplant. 15 However, to the best of our knowledge, longitudinal data are lacking describing both long-term changes in IS, and predictors of IS, in patients with T1D who have undergone long-term successful islet transplantation. A better understanding of clinical, modifiable, and/or physiological factors associated with recipients' improved IS could inform future research on interventions aimed at providing more durable islet graft function. Therefore, using longitudinal granular data from patients enrolled in islet transplant clinical trials, 13 the current study (1) investigated changes in IS by using HOMA-IR and SI is OGTT, up to a mean of 4 years following islet transplant and (2) ).
| MATERIALS AND METHODS

| Study design and participants
The current study is a secondary analysis of existing data extracted from the medical records of 22 patients with T1D who (1) 20, 21 Pretransplant data used in the current analysis were those closest to the initial transplant. Follow-up after initial islet transplant ranged up to 9.4 years. At the end of 2014, 10 of the 22 patients were no longer active in the clinical trials due to: graft failure (n = 6), adverse events (n = 1), malignancy (n = 1), death (n = 1), or withdrawal (n = 1 biomarker levels were calculated by using all data available from the 3 time points.
| Statistical analysis
All analyses were performed by using SAS (version 9.4, Cary, NC 3 | RESULTS
| Patient characteristics
Most were female (n = 18), and all but 1 were Non-Hispanic white. The mean (SD) age and duration of T1D at the time of initial transplant were 45.3 (11.9) years and 27.9 (11.8) years, respectively (Table 1 ).
Both pretransplant and posttransplant patients were on average normotensive and had normal lipid levels, although many were using antihypertensives (n = 12 pre/14 post) and/or statins (n = 12 pre/17 post).
Body mass index pre-and posttransplant was within the normal range. Estimated glomerular filtration rate levels were, on average, above 80 mL min Table 2 presents the average levels of each biomarker at the 3 time points and mean changes over time. There were no significant changes in undercarboxylated OC, carboxylated OC, total OC, or IGF-1. There were trends toward a decrease in RANKL (P = .09) and an increase in adiponectin (P = .06). There was a significant decrease in leptin (P < .0001), specifically from pre-to 1-week post transplant. No significant changes were observed in fasting insulin or BMI. baseline demonstrated a quadratic association with HOMA-IR after transplant (P = .001; Figure 2A ), such that HOMA-IR was slightly negatively associated with RANKL at the lowest levels of RANKL, while positively associated with RANKL at higher levels of RANKL.
| Biomarkers
| Metabolic outcomes
| Associations with Homeostasis Model Assessment for Insulin Resistance
Fasting C-peptide also had a quadratic association with HOMA-IR (P = .01; Figure 3A) , with a stronger positive association at higher fasting C-peptide levels. Exenatide dose was negatively associated with HOMA-IR in men but had a null association in women (sex interaction P = .01). However, female sex had a negative association with HOMA-IR (ie, they were more insulin sensitive than men, P = .001). Further adjusting for the type of metabolic test used to calculate HOMA-IR did not change the results. 
| Associations with Simple Index of Insulin Sensitivity from the oral glucose tolerance test
Adjusting for age and BMI (Table 4) , mean leptin at baseline demonstrated a quadratic association with SI is OGTT posttransplant (P = .01; Figure 2B ), with the negative association being stronger at lower leptin levels and the association plateauing at higher leptin levels. 
| DISCUSSION
To the best of our knowledge, this is the first study to investigate longterm changes in IS by using HOMA-IR and SI is OGTT in patients with T1D who have received islet cell transplantation (even if requiring small doses of exogenous insulin immediately after the transplants) and to determine clinical, modifiable, and/or physiological factors associated with long-term changes in IS following islet transplant in these patients. In summary, IS as measured by SI is OGTT improved within 1 year following first transplant and remained stable at this improved level for up to a mean of 4 years, whereas IS as measured by HOMA-IR remained stable (ie, did not worsen) over the entire follow-up. This is particularly important given that decreasing IS is associated with longer T1D duration. 9 Insulin sensitivity after transplant was associated with both potentially modifiable factors and with transplant outcomes. These results need to be confirmed by using HIEG clamp studies in the decade following islet transplant but indicate potential clinical benefits of optimizing IS surrounding transplant.
Our study is in agreement with prior research that also demonstrated IS (peripheral, hepatic, and total) improved immediately postislet transplant, as quantified by the FSIVGT 23 and the HIEG clamp 15 ; however, both of these studies were limited to at most 1-year follow-up. Research in a more heterogeneous sample, where 4 of the 10 participants were islet-after-kidney recipients, similarly found improvements in IS measured by FSIVGT within 12 months following islet transplant. 24 The beneficial effect that islet transplant has on IS has been hypothesized to be a result of restoring endogenous insulin, specifically the resolution of hyperglycaemia and normalization of insulin's suppression of NEFA production. 23 The current study interestingly found a significant improvement in IS as measured by SI is OGTT, but no change in IS as measured by HOMA-IR. Further mechanistic research is needed to determine if islet transplant has differential effects on parameters quantified by SI is OGTT's stimulated metabolic outcomes, specifically muscle and adipose tissue glucose metabolism, versus parameters captured by HOMA-IR, specifically fasting hepatic glucose production. 6, 25 Or perhaps SI is OGTT may be a more sensitive measure of insulin action in this population.
With respect to clinical outcomes, as expected, HbA1c and fasting C-peptide improved after transplant. 26 Among individuals with T1D, previous research has shown that higher IS (HIEG clamp) was associated with lower glycosylated haemoglobin. 27 The current study similarly found that for patients undergoing islet transplant for T1D, enhanced IS following islet transplant was associated with improved glycaemic control. Lower IS was significantly associated with greater fasting C-peptide, and in a smaller subgroup, with greater stimulated C-peptide as well. In this case, C-peptide, a marker of endogenous insulin secretion, might therefore also be interpreted as a marker for betacell demand or stress because it is generally accepted that impaired IS requires higher levels of insulin, increasing demand on beta-cells. 28 The quadratic association between fasting C-peptide and IS as measured by both HOMA-IR and SI is OGTT (Figure 3 ) demonstrates that the positive and negative associations, respectively, are stronger above the normal value of fasting C-peptide, about 1.0 ng/mL, such that it is the patients who are less sensitive to insulin that are placing more demand on their islet grafts' beta-cells. Therefore, improving patients' IS surrounding islet transplant could potentially lower the demand on beta-cells, extending islet graft function and survival.
Other islet transplant trials have shown that in patients receiving more than 600,000 IEQs in total, 75 to 80% reached insulin independence, compared with 55% who received fewer. 29 The current study found that having more IEQs/kg transplanted was also associated with improved IS. This may be a function of a greater number of IEQs providing a more rapid resolution of hyperglycaemia and suppression of NEFA production as previously discussed. 23 Also demonstrated was a sex difference in the relationship of exenetide with IS as calculated by HOMA-IR, such that exenatide was associated with improved IS among men, but not in women. In comparison, exenatide was associated with improved IS as calculated by SI is OGTT in both sexes. Exenatide has been previously shown to improve IS (HIEG clamp) by 40% in patients with T1D. 30 The lesser impact of exenatide specifically on IS in women following islet transplant may be a function of their already significantly higher IS compared with the men in the present sample.
The current study is innovative in that it investigated the association of IS posttransplant with IS-related biomarkers measured at baseline. The demonstrated association between HOMA-IR and RANKL (specifically at higher levels of RANKL) is similar to the findings of an experimental study, whereby the blocking or deletion of RANKL signalling specifically in the liver in mice led to significantly lower HOMA-IR compared with wild-type mice on a high fat diet. 18 In an epidemiological study, higher baseline circulating levels of RANKL were found to be associated with greater odds of developing type 2 diabetes over a 15-year period. 18 Further research is needed to determine if the quadratic association between HOMA-IR and RANKL (Figure 2A) reflects various thresholds where there is an optimal circulating range of RANKL, above and below which IS decreases. Regarding leptin, similar to the current study, previous literature found a positive association between leptin and HOMA-IR among nondiabetic individuals. 16 The current study also found a negative, quadratic association between leptin and SI is OGTT ( Figure 2B ). Again, further research is needed to clarify if the association is capturing a threshold effect where below a certain leptin concentration, the negative association of leptin with IS is stronger.
Based on our findings, islet transplant outcomes may be optimized by considering both transplant and patient modifiable factors that enhance patients' IS. Maximizing the number of IEQs transplanted in the patient's first transplant may result in better IS, which then may lead to lower fasting C-peptide and better glycaemic control as found in this study, as well as potentially longer lasting graft function.
Prescribing and titrating exenatide to the maximum tolerable dose may be an option for improving IS after transplant and, potentially, pretransplant. Another option for enhancing patients' long-term IS after transplant may be lowering leptin and RANKL levels surrounding first transplant by prescription of healthy diet 31 and exercise. 31, 32 Although this study does not utilize the gold standard for measuring IS (HIEG was not part of the clinical trial protocols), the employed metrics, HOMA-IR and SI is OGTT, have been documented to be highly correlated with HIEG clamp measures in nondiabetic, nonobese individuals. 5, 7 The trends in, and associations with, HOMA-IR and SI is OGTT remained robust even after adjusting for the minimal exogenous insulin therapy patients were requiring shortly after the islet transplants, supporting the use of these mathematical models in this patient population after T1D was reversed. Just as HOMA and SI is OGTT were not calculated pretransplant as they are not valid in the presence of T1D, eGDR was not calculated posttransplant as it was specifically derived and validated for use in those with T1D. 8 As a standard IVGTT (not a FSIVGT) was part of the clinical trial protocols, with fewer blood samples and without a bolus of insulin, we were not able to calculate the Insulin Sensitivity Index by using minimal modelling. As is the case for all islet transplant clinical trials, a control group was not available, because it is unethical to randomize patients to either islet transplant or an alternative treatment for hypoglycaemic unawareness given that to be eligible for islet transplantation, the all available data were able to be analysed despite unequal follow-up times using the mixed-effects modelling of repeated measures.
In summary, IS as measured by SI is OGTT improved within 1 year of functionally curing T1D via islet transplant and remained improved, while IS as measured by HOMA-IR did not worsen, over several years of follow-up. Furthermore, improved IS was associated with better glycaemic control and lower fasting C-peptide. However, these results need to be confirmed by using HIEG clamp studies over the decade following islet cell transplant. With the long-term goal being to lessen the requirement of islets transplanted along with the need for subsequent islet transplants, utilizing clinical and behavioural modifications pre-and posttransplant to improve patients' IS may be considered.
Future research is needed to confirm the clinical significance of such interventions on subsequent clinical outcomes in this patient population.
